## Competition Authority Clears the Acquisition of Martek Biosciences Corporation

The Competition Authority has cleared the proposed acquisition whereby Koninklijke DSM N.V. would acquire sole control of Martek Biosciences Corporation. The transaction was notified by the parties under the Competition Act 2002 on 17 January 2011.

The Authority has formed the view that the proposed transaction will not lead to a substantial lessening of competition in any markets for goods or services in the State. The Authority will publish a public version of the determination on its website (www.tca.ie) no later than 10 April 2011 after allowing the parties the opportunity to request that confidential information is removed from the published version.

## Notes

Koninklijke DSM N.V., headquartered in the Netherlands, is a chemical company specializing in life sciences and material sciences. Koninklijke DSM N.V.'s business activities can be grouped into five areas: nutrition; pharmaceuticals; performance materials; polymer intermediates; and, base chemicals and materials. Koninklijke DSM N.V. supplies the following products in the State: pharmaceutical ingredients; anti-infectives; animal feed products; personal care ingredients; human nutrition and health products; and, infant nutrition.

Martek Biosciences Corporation, headquartered in the United States, manufactures and sells nutritional products. In particular, Martek Biosciences Corporation has developed and patented a strain of algae that produce oils rich in docosahexaeonic acid and a strain of fungus that produces oils rich in arachidonic acid. In the State, Martek Biosciences Corporation supplies omega-3 docosahexaeonic acid and omega-6 arachidonic acid for use in the manufacture of infant and growing-up formulae.

## For further information contact:

Clodagh Coffey, Communications Manager, The Competition Authority Tel: 018045406
email: cc@tca.ie

